We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

33 hedge funds and large institutions have $11.8M invested in Rein Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

6% more funds holding

Funds holding: 31 → 33 (+2)

0.02% less ownership

Funds ownership: 0.4% → 0.38% (-0.02%)

25% less capital invested

Capital invested by funds: $15.7M → $11.8M (-$3.88M)

Holders
33
Holders Change
+2
Holders Change %
+6.45%
% of All Funds
0.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
12
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$258K
2
ECM
Endurant Capital Management
California
+$199K
3
State Street
State Street
Massachusetts
+$183K
4
Squarepoint
Squarepoint
New York
+$133K
5
TCIM
TIAA CREF Investment Management
New York
+$66.9K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$494K
2
LCM
Laurion Capital Management
New York
-$401K
3
MCM
Masters Capital Management
Georgia
-$401K
4
Charles Schwab
Charles Schwab
California
-$165K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$135K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$9K +$6.23K +26 +163%
JP Morgan Chase
27
JP Morgan Chase
New York
$9K +$10.1K +42 New
Macquarie Group
28
Macquarie Group
Australia
$8K +$9.59K +40 New
Parallax Volatility Advisers
29
Parallax Volatility Advisers
California
$8K +$9.59K +40 New
TRCT
30
Tower Research Capital (TRC)
New York
$8K +$9.59K +40 New
Barclays
31
Barclays
United Kingdom
$6K +$5.75K +24 +400%
AIP
32
Ameritas Investment Partners
Nebraska
$5K +$5.27K +22 New
AG
33
Advisor Group
Arizona
$2K +$1.92K +8 New
Millennium Management
34
Millennium Management
New York
– -$494K -1,847 Closed
LCM
35
Laurion Capital Management
New York
– -$401K -1,500 Closed
MCM
36
Masters Capital Management
Georgia
– -$401K -1,500 Closed
Charles Schwab
37
Charles Schwab
California
– -$165K -615 Closed
Bank of New York Mellon
38
Bank of New York Mellon
New York
– -$135K -501 Closed
NFA
39
Nationwide Fund Advisors
Ohio
– -$34K -127 Closed
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
– -$6K -22 Closed
1
2

RNTX Hedge Fund Activity: Q4 2017 in Review

33 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2017, worth a combined $11.8M — down 25% from $15.7M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new RNTX positions and 7 closed out — a net gain of 2 holders — while 12 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $258K. The largest seller was Millennium Management, exiting entirely with an estimated $494K sold.

  • 33 institutional investors held Rein Therapeutics (RNTX) as of Q4 2017, up from 31 in Q3 2017.
  • Funds reported $11.8M of Rein Therapeutics stock for Q4 2017, down 25% quarter-over-quarter.
  • 9 funds opened new Rein Therapeutics positions in Q4 2017 and 7 closed out, a net change of +2 holders.
  • The largest Rein Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $258K added.
  • The largest Rein Therapeutics seller in Q4 2017 was Millennium Management, an estimated $494K sold.

Based on aggregated 13F filings for Q4 2017.